Clinical Trials Logo
  1. Home
  2. Chronic Hepatitis C Infection
  3. NCT00854087

Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

Chronic Hepatitis C Infection Clinical Trial

Official title:
A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

Clinical Trial Summary

Current treatment of chronic liver disease relies upon removing the primary insult to the liver (e.g., alcohol) or treating the underlying viral infection (HBV, HCV, etc.). However, in the case of hepatitis C, a significant number of individuals will not clear the virus with current approved standard antiviral therapy, leaving them no options to manage their hepatic fibrosis, which can progress to cirrhosis and ultimately hepatocellular carcinoma (HCC). Fuzheng Huayu has been used in numerous studies in China and has been found to have a satisfactory prophylaxis effect on the chronic liver injury and formed liver fibrosis in rats and humans. In addition, it enhances the degradation of liver fibrosis and protects hepatocytes from injury and death, manifesting as decreasing of ALT and AST, and enhancement of albumin level. In addition, preliminary studies indicate that the Fuzheng Huayu has a good safety and tolerability profile with promising efficacy. The number of patients failing Interferon based therapy (i.e. not achieving SVR) is increasing. There are no approved standard of care treatment options for this population nor for patients who are intolerant or unwilling to receive Interferon; thus they are at higher risk for the progression of fibrosis. Moreover, there are no approved therapies to treat hepatic fibrosis, but basic research is exploring the pathophysiological mechanisms. Fuzheng Huayu is easy to administer, with a good safety and efficacy profile against fibrosis. Therefore, the investigators propose to further study the safety and efficacy profile of Fuzheng Huayu in a randomized, placebo-controlled, double blind study in Chronic Hepatitis C patients with hepatic fibrosis who have failed prior anti-HCV therapy or are intolerant or refuse Interferon based therapy. The primary objective of this study is to establish the safety and efficacy of Fuzheng Huayu treatment in chronic hepatitis C subjects who have failed prior anti-HCV therapy or cannot receive or refused Interferon based therapy in improving liver fibrosis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00854087
Study type Interventional
Source SCTI Research Foundation
Contact
Status Completed
Phase Phase 2
Start date August 2010
Completion date August 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02216422 - A Study to Evaluate Chronic Hepatitis C Infection in Cirrhotic Adults With Genotype 1b Infection Phase 3
Completed NCT02219503 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis Phase 3
Completed NCT01700179 - Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants Phase 1
Completed NCT02486406 - A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects Phase 2/Phase 3
Completed NCT01704755 - A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis Phase 3
Completed NCT01221298 - A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) Phase 2
Completed NCT01225380 - A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Phase 2
Completed NCT01716585 - A Study to Evaluate Chronic Hepatitis C Infection Phase 3
Completed NCT02065999 - Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
Completed NCT01715415 - A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults Phase 3
Completed NCT01453075 - Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I) Phase 1
Completed NCT01011166 - Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004) Phase 2
Completed NCT00557583 - Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults Phase 1
Terminated NCT01586325 - A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients Phase 1
Recruiting NCT02583685 - Switching Regimen in Treating Cirrhotic HCV GT1b Subjects Phase 2
Recruiting NCT02578693 - Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
Completed NCT02576314 - Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients Phase 3
Not yet recruiting NCT01835938 - Clinical Investigation of Erlotinib as an HCV Entry Inhibitor Phase 1/Phase 2
Completed NCT01055821 - Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients Phase 2
Completed NCT01854697 - A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before Phase 3